TitleEstrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
Publication TypeJournal Article
Year of Publication2010
AuthorsChlebowski, RT, Anderson, GL, Gass, M, Lane, DS, Aragaki, AK, Kuller, LH, Manson, JAE, Stefanick, ML, Ockene, J, Sarto, GE, Johnson, KC, Wactawski-Wende, J, Ravdin, PM, Schenken, R, Hendrix, SL, Rajkovic, A, Rohan, TE, Yasmeen, S, Prentice, RL
JournalJAMA : the journal of the American Medical Association
Volume304
Issue15
Pagination1684-92
Date Published2010 Oct 20
KeywordsUnited States
Abstract

In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported.